News/ News/ R&D Otsuka has high hopes for its ‘drug creation engine’ acquisition Dominic Tyer antibody, Antibody Engineering, Hierotope, kidney disease, nephrology, Otsuka, Visterra 0 Comment Otsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug Share X Otsuka has high hopes for its ‘drug creation engine’ acquisition https://pharmaphorum.com/news/otsuka-biotech-visterra-hierotope/